• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289).
  
• Mutation; HGNC; HGNC:1773; CDK4; Simple; p.Arg24Leu (c.71G>T); ClinVar=VCV000376377; Zygosity=Unspecified (PubMed=21156289).
  
• Mutation; HGNC; HGNC:11355; STAG2; Simple; p.Lys1083Ter (c.3247A>T); Zygosity=Unspecified (PubMed=27500726).
  

PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023; PMCID=PMC3026446
Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W., Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K., Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A., Sosman J.A., Nathanson K.L., Herlyn M.
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Cancer Cell 18:683-695(2010)

PubMed=27500726; DOI=10.1038/nm.4155; PMCID=PMC5014622
Shen C.-H., Kim S.H., Trousil S., Frederick D.T., Piris A., Yuan P., Cai L., Gu L., Li M., Lee J.H., Mitra D., Fisher D.E., Sullivan R.J., Flaherty K.T., Zheng B.
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
Nat. Med. 22:1056-1061(2016)